Acquisition of Rights to Actavis' Portfolio

AstraZeneca COMPLETES acquiSITION OF rights to actavis' Branded respiratory
portfolio in THE US AND CANADA

Acquisition strengthens AstraZeneca's aclidinium respiratory franchise and adds

immediate revenues with long-term growth potential

AstraZeneca today announced that it has completed the transaction to acquire the
rights to Actavis' branded respiratory business in the US and Canada.

As previously announced (http://www.astrazeneca.com/Media/Press
-releases/Article/20150205--astrazeneca-to-acquire-rights-to-actavis-branded
-respiratory-portfolio-in-the-US-and-Canada), the strategic transaction
strengthens AstraZeneca's respiratory franchise globally and builds on the
acquisition of Almirall's respiratory portfolio in 2014 by extending the
company's development and commercialisation rights into the US for both Tudorza
Pressair and Duaklir Genuair.

AstraZeneca owns the development and commercial rights in the US and Canada to
TudorzaTM PressairTM (aclidinium bromide inhalation powder), a twice-daily long
-acting muscarinic antagonist (LAMA) for chronic obstructive pulmonary disease
(COPD), and to Daliresp® (roflumilast), the only once-daily oral PDE4 inhibitor
currently on the market for COPD, in the US. AstraZeneca also owns the
development rights in the US and Canada for LAS40464, the combination of a fixed
dose of aclidinium with formoterol long acting beta agonist (LAMA/LABA) in a dry
powder inhaler, which is approved in the EU under the brand name Duaklir®
Genuair®.

On completion of the acquisition, AstraZeneca is paying Actavis $600 million of
initial consideration and agreed to pay low single-digit royalties above a
certain revenue threshold. AstraZeneca has also paid Actavis an additional $100
million for a number of contractual consents and approvals, including certain
amendments to the ongoing collaboration agreements between AstraZeneca and
Actavis.

About Tudorza Pressair
Tudorza Pressair (aclidinium bromide inhalation powder) 400 mcg is an
anticholinergic indicated for the long-term maintenance treatment of
bronchospasm associated with chronic obstructive pulmonary disease (COPD),
including chronic bronchitis and emphysema. When given by inhalation, aclidinium
produces bronchodilation by inhibiting the muscarinic M3 receptor in the airway
smooth muscle. Aclidinium is rapidly hydrolyzed in human plasma into two major
inactive metabolites.

Tudorza is administered using a multiple-dose dry powder inhaler, Pressair,
which delivers 60 doses of aclidinium bromide powder for inhalation. The
Pressair inhaler has a colored control window and audible "click" which confirm
successful inhalation of the dose and a dose indicator to let patients know how
many doses remain in the inhaler.

About Daliresp
Daliresp (500mcg) is a selective PDE4 inhibitor that is indicated as a treatment
to reduce the risk of exacerbations in patients with severe COPD associated with
chronic bronchitis and a history of exacerbations. Daliresp is a once-daily oral
tablet and is the first and only selective PDE4 inhibitor approved by the FDA.

While the specific mechanism by which Daliresp exerts its therapeutic action in
COPD patients is not well defined, it is thought to be related to the effects of
increased intracellular cyclic AMP in the lung cells. Daliresp is not a steroid,
is not a bronchodilator and is not indicated for the relief of acute
bronchospasm.

About COPD
COPD (chronic obstructive pulmonary disease) is a progressive disease associated
mainly with tobacco smoking, air pollution or occupational exposure, which can
cause obstruction of airflow in the lungs resulting in debilitating bouts of
breathlessness. It affects an estimated 300 million people worldwide and is
predicted to be the third leading cause of death by 2020. Although COPD is
widely regarded as a disease of the elderly, 50 per cent of patients are
estimated to be between 50 and 65 years of age, meaning half of the COPD
population is likely to be affected at a stage in their life when they are at
the peak of their earning potential and are likely to have major family
responsibilities.

About Actavis
Actavis Plc (NYSE:ACT), headquartered in Dublin, Ireland, is a unique specialty
pharmaceutical company focused on developing, manufacturing and commercializing
high quality affordable generic and innovative branded pharmaceutical products
for patients around the world.

Actavis markets a broad portfolio of branded and generic pharmaceuticals and
develops innovative medicines for patients suffering from diseases principally
in the central nervous system, gastroenterology, women's health, urology,
cardiovascular, respiratory and anti-infective therapeutic categories. The
Company is an industry leader in product research and development, with one of
the broadest brand development pipelines in the pharmaceutical industry, and a
leading position in the submission of generic product applications. Actavis has
commercial operations in more than 60 countries and operates more than 30
manufacturing and distribution facilities around the world.

For more information, visit Actavis' website at www.actavis.com.

About AstraZeneca
AstraZeneca is a global, innovation-driven biopharmaceutical business that
focuses on the discovery, development and commercialisation of prescription
medicines, primarily for the treatment of cardiovascular, metabolic,
respiratory, inflammation, autoimmune, oncology, infection and neuroscience
diseases. AstraZeneca operates in over 100 countries and its innovative
medicines are used by millions of patients worldwide. For more information
please visit: www.astrazeneca.com

CONTACTS

Media Enquiries
Esra Erkal-Paler                     +44 20 7604 8030 (UK/Global)
Vanessa Rhodes                    +44 20 7604 8037 (UK/Global)
Ayesha Bharmal                     +44 20 7604 8034 (UK/Global)
Michele Meixell                       +1 302 885 2677 (US)

Jacob Lund                             +46 8 553 260 20 (Sweden)

Investor Enquiries
Thomas Kudsk Larsen            +44 20 7604 8199       mob: +44 7818 524185
Karl Hård                                 +44 20 7604 8123    mob: +44 7789
654364
Eugenia Litz                            +44 20 7604 8233       mob: +44 7884
735627
Craig Marks                             +44 20 7604 8591       mob: +44 7881
615764
Christer Gruvris                       +44 20 7604 8126       mob: +44 7827
836825

03 March 2015

-ENDS-